A Phase 3 interventional study of Azilsartan medoxomil and chlorthalidone and Olmesartan medoxomil and hydrochlorothiazide in Safety, sponsored by Takeda. Completed at 55 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-13.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Renal Insufficiency by Takeda — 1 open to participants now, 1 under way, none of them phase 3. Renal Insufficiency · Takeda.
Among the 12 studies in Renal Insufficiency by Takeda, this one is the 2nd largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2011, is one of 2 in phase 3, and was the 5th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →1 of the 12 studies in Renal Insufficiency by Takeda is open now, in 7 countries. Recruiting first, the newest first:
Takeda · Sites in Belgium, Estonia, France and 4 more countries
Ages 18+
By country, each count listing its studies:
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 153 is above the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 48 across the 11 interventional studies, 10 across the 1 observational. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
1 of the studies in Renal Insufficiency by Takeda that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06243731TakedaA Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Renal Insufficiency by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate long term safety and tolerability of azilsartan medoxomil and chlorthalidone, once daily (QD), compared with olmesartan medoxomil and hydrochlorothiazide in hypertensive participants with moderate renal impairment.
A major component of blood pressure regulation is the renin-angiotensin-aldosterone system (RAAS). Drugs that modulate the RAAS are used commonly worldwide for the treatment of hypertension. TAK-491 (azilsartan medoxomil) is a prodrug of TAK-536 (azilsartan), an angiotensin II receptor blocker (ARB). Azilsartan medoxomil is being evaluated by Takeda to treat participants with essential hypertension.
Chlorthalidone is an orally administered thiazide-like diuretic agent, and long-term outcomes trials show blood pressure reductions associated with chlorthalidone treatment reduce risk of cardiovascular morbidity and mortality.
Hypertensive patients with moderate renal impairment are a relatively more severe and resistant hypertension population, and may benefit from effective fixed-dose combination treatments such as an ARB plus a diuretic for blood pressure control.
Participants will be randomized to receive azilsartan medoxomil and chlorthalidone or olmesartan medoxomil and hydrochlorothiazide for up to 52 weeks to evaluate long term safety of azilsartan medoxomil and chlorthalidone. A titration-to-target blood pressure approach will be used to guide the titration of study medication in this trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
United States and Europe: Azilsartan medoxomil 20 mg plus chlorthalidone 12.5 mg fixed dose combination tablets, titrated up to azilsartan medoxomil 40 mg plus chlorthalidone 25 mg orally, once daily for up to 52 weeks.
Drug: Azilsartan medoxomil and chlorthalidone
United States: Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg fixed dose combination tablets, titrated up to olmesartan medoxomil 40 mg plus hydrochlorothiazide 25 mg orally, once daily for up to 52 weeks. Europe: Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg fixed dose combination tablets, titrated up to olmesartan medoxomil 20 mg plus hydrochlorothiazide 25 mg orally, once daily for up to 52 weeks.
Drug: Olmesartan medoxomil and hydrochlorothiazide
Drug pages: Azilsartan medoxomil · Chlorthalidone
Fixed-dose combination tablets.
Also known as: TAK-491CLD
Drug pages: Olmesartan Medoxomil · Hydrochlorothiazide
Fixed-dose combination tablets.
Also known as: Olmesartan medoxomil, Hydrochlorothiazide, Benicar hydrochlorothiazide, Olmetec Plus
Number of Participants With at Least 1 Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have a causal relationship with this treatment. A serious AE is defined as any untoward medical occurrence that resulted in death, was life threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability or incapacity, led to a congenital anomaly/birth defect or was an important medical event that may have required intervention to prevent any of items above.
Time frame: From the first dose of open-label study drug until 14 days (or 30 days for a serious adverse event) after the last dose of open- label study drug (up to 56 weeks).
Percentage of Participants at Final Visit Who Achieve Target Systolic Blood Pressure <130 mm Hg
Systolic blood pressure is the arithmetic mean of the 3 serial sitting systolic blood pressure measurements. Percentage of participants who achieve a sitting clinic systolic blood pressure response defined as less than 130 mm Hg at Week 52.
Time frame: Week 52
Percentage of Participants at Final Visit Who Achieved Target Diastolic Blood Pressure <80 mm Hg
Diastolic blood pressure is the arithmetic mean of the 3 serial sitting diastolic blood pressure measurements. Percentage of participants at Week 52 who achieved a sitting clinic diastolic blood pressure response, defined as less than 80 mm Hg.
Time frame: Week 52
Percentage of Participants at Final Visit Who Achieved Both a Clinic Systolic and Diastolic Blood Pressure Response
Systolic/diastolic blood pressure is the arithmetic mean of the 3 serial sitting systolic/diastolic blood pressure measurements. Percentage of participants who achieved both a sitting clinic systolic and diastolic blood pressure response, defined as systolic blood pressure less than 130 mm Hg and diastolic blood pressure less than 80 mm Hg at Week 52.
Time frame: Week 52
Participants took part in the study at 46 investigative sites in the United States, Germany, Latvia, Lithuania, Poland, Slovakia, and the Ukraine from 02 March 2011 to 11 October 2012.
| Milestone | Azilsartan Medoxomil + Chlorthalidone | Olmesartan Medoxomil + Hydrochlorothiazide |
|---|---|---|
| Started | 77 | 76 |
| Completed | 61 | 60 |
| Not completed | 16 | 16 |
| Withdrew: Adverse event | 10 | 11 |
| Withdrew: Voluntary withdrawal | 5 | 4 |
| Withdrew: Major protocol deviation | 0 | 1 |
| Withdrew: Other | 1 | 0 |
An AE is any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have a causal relationship with this treatment. A serious AE is defined as any untoward medical occurrence that resulted in death, was life threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability or incapacity, led to a congenital anomaly/birth defect or was an important medical event that may have required intervention to prevent any of items above.
| participants | Azilsartan Medoxomil + Chlorthalidone | Olmesartan Medoxomil + Hydrochlorothiazide |
|---|---|---|
| Adverse Events | 68 | 58 |
| Adverse Events Leading to Discontinuation | 17 | 15 |
| Serious Adverse Events | 8 | 9 |
| Serious Adverse Events Leading to Discontinuation | 5 | 4 |
| Death | 0 | 1 |
Systolic blood pressure is the arithmetic mean of the 3 serial sitting systolic blood pressure measurements. Percentage of participants who achieve a sitting clinic systolic blood pressure response defined as less than 130 mm Hg at Week 52.
| percentage of participants | Azilsartan Medoxomil + Chlorthalidone | Olmesartan Medoxomil + Hydrochlorothiazide |
|---|---|---|
| Percentage of Participants at Final Visit Who Achieve Target Systolic Blood Pressure <130 mm Hg | 69.3 (57.6 to 79.5) | 78.4 (67.3 to 87.1) |
Diastolic blood pressure is the arithmetic mean of the 3 serial sitting diastolic blood pressure measurements. Percentage of participants at Week 52 who achieved a sitting clinic diastolic blood pressure response, defined as less than 80 mm Hg.
| percentage of participants | Azilsartan Medoxomil + Chlorthalidone | Olmesartan Medoxomil + Hydrochlorothiazide |
|---|---|---|
| Percentage of Participants at Final Visit Who Achieved Target Diastolic Blood Pressure <80 mm Hg | 80.0 (69.2 to 88.4) | 87.8 (78.2 to 94.3) |
Systolic/diastolic blood pressure is the arithmetic mean of the 3 serial sitting systolic/diastolic blood pressure measurements. Percentage of participants who achieved both a sitting clinic systolic and diastolic blood pressure response, defined as systolic blood pressure less than 130 mm Hg and diastolic blood pressure less than 80 mm Hg at Week 52.
| percentage of participants | Azilsartan Medoxomil + Chlorthalidone | Olmesartan Medoxomil + Hydrochlorothiazide |
|---|---|---|
| Percentage of Participants at Final Visit Who Achieved Both a Clinic Systolic and Diastolic Blood Pressure Response | 58.7 (46.7 to 69.9) | 73.0 (61.4 to 82.6) |
Collected over From the first dose of open-label study drug until 14 days (or 30 days for a serious adverse event) after the last dose of open-label study drug (up to 56 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Azilsartan Medoxomil + Chlorthalidone | — | 8/77 (10.4%) | 52/77 (67.5%) |
| Olmesartan Medoxomil + Hydrochlorothiazide | — | 9/76 (11.8%) | 41/76 (53.9%) |
| Event | Azilsartan Medoxomil + Chlorthalidone | Olmesartan Medoxomil + Hydrochlorothiazide |
|---|---|---|
| Angina pectorisCardiac disorders | 0/77 | 2/76 |
| Angina unstableCardiac disorders | 2/77 | 1/76 |
| Coronary artery diseaseCardiac disorders | 2/77 | 1/76 |
| Atrial tachycardiaCardiac disorders | 0/77 | 1/76 |
| BradycardiaCardiac disorders | 0/77 | 1/76 |
| VomitingGastrointestinal disorders | 0/77 | 1/76 |
| ConcussionInjury, poisoning and procedural complications | 0/77 | 1/76 |
| Hip fractureInjury, poisoning and procedural complications | 0/77 | 1/76 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/77 | 1/76 |
| Pituitary tumour recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/77 | 1/76 |
| Event | Azilsartan Medoxomil + Chlorthalidone | Olmesartan Medoxomil + Hydrochlorothiazide |
|---|---|---|
| Blood creatinine increasedInvestigations | 34/77 | 29/76 |
| HeadacheNervous system disorders | 8/77 | 2/76 |
| DizzinessNervous system disorders | 6/77 | 5/76 |
| DiarrhoeaGastrointestinal disorders | 1/77 | 4/76 |
| AstheniaGeneral disorders | 3/77 | 4/76 |
| PharygitisInfections and infestations | 0/77 | 4/76 |
| HyperuricaemiaMetabolism and nutrition disorders | 3/77 | 4/76 |
| BronchitisInfections and infestations | 4/77 | 3/76 |
| HypokalaemiaMetabolism and nutrition disorders | 4/77 | 3/76 |
| HypotensionVascular disorders | 4/77 | 3/76 |
| Age Continuous(years) | Azilsartan Medoxomil + Chlorthalidone | Olmesartan Medoxomil + Hydrochlorothiazide | Total |
|---|---|---|---|
| Mean | 67.9 ± 8.24 | 68.9 ± 9.10 | 68.4 ± 8.66 |
| Age, Customized(participants) | Azilsartan Medoxomil + Chlorthalidone | Olmesartan Medoxomil + Hydrochlorothiazide | Total |
|---|---|---|---|
| <45 years | 0 | 1 | 1 |
| ≥45 to <65 years | 21 | 18 | 39 |
| ≥65 to <75 years | 38 | 39 | 77 |
| ≥75 years | 18 | 18 | 36 |
| Sex: Female, Male(Participants) | Azilsartan Medoxomil + Chlorthalidone | Olmesartan Medoxomil + Hydrochlorothiazide | Total |
|---|---|---|---|
| Female | 45 | 31 | 76 |
| Male | 32 | 45 | 77 |
| Race/Ethnicity, Customized(participants) | Azilsartan Medoxomil + Chlorthalidone | Olmesartan Medoxomil + Hydrochlorothiazide | Total |
|---|---|---|---|
| White | 57 | 62 | 119 |
| Black or African American | 18 | 12 | 30 |
| Asian | 2 | 2 | 4 |
| Region of Enrollment(participants) | Azilsartan Medoxomil + Chlorthalidone | Olmesartan Medoxomil + Hydrochlorothiazide | Total |
|---|---|---|---|
| Germany | 10 | 9 | 19 |
| Latvia | 4 | 5 | 9 |
| Lithuania | 5 | 2 | 7 |
| Poland | 7 | 6 | 13 |
| Slovakia | 6 | 6 | 12 |
| Ukraine | 6 | 11 | 17 |
| United States | 39 | 37 | 76 |
| Weight(kg) | Azilsartan Medoxomil + Chlorthalidone | Olmesartan Medoxomil + Hydrochlorothiazide | Total |
|---|---|---|---|
| Mean | 83.54 ± 17.894 | 90.14 ± 21.587 | 86.82 ± 20.025 |
| Height(cm) | Azilsartan Medoxomil + Chlorthalidone | Olmesartan Medoxomil + Hydrochlorothiazide | Total |
|---|---|---|---|
| Mean | 165.7 ± 9.65 | 168.7 ± 9.48 | 167.2 ± 9.65 |
| Body Mass Index (BMI)(kg/m^2) | Azilsartan Medoxomil + Chlorthalidone | Olmesartan Medoxomil + Hydrochlorothiazide | Total |
|---|---|---|---|
| Mean | 30.44 ± 6.226 | 31.57 ± 6.524 | 31.00 ± 6.380 |
8 further baseline measures are reported on the registry.
The record gives a start of Mar 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Azilsartan medoxomil · Chlorthalidone